Lactic acid bacteria as live vaccines - PubMed (original) (raw)
Affiliations
- PMID: 11464916
Free article
Review
Lactic acid bacteria as live vaccines
A Mercenier et al. Curr Issues Mol Biol. 2000 Jan.
Free article
Abstract
Mucosal routes for vaccine delivery offer several advantages over systemic inoculation from both immunological and practical points of view. The development of efficient mucosal vaccines therefore represents a top prority in modern vaccinology. One way to deliver protective antigens at the mucosal surfaces is to use live bacterial vectors. Until recently most of these were derived from attenuated pathogenic microorganisms. As an alternative to this strategy, non-pathogenic food grade bacteria such as lactic acid bacteria (LAB) are being tested for their efficacy as live antigen carriers. The LABVAC european research network is presently comparing the vaccine potential of Lactococcus lactis, Streptococcus gordonii and Lactobacillus spp. To date, it has been shown that systemic and mucosal antigen-specific immune responses can be elicited in mice through the nasal route using the three LAB systems under study. Data on successful oral and vaginal immunisations are also accumulating for L. lactis and S. gordonii, respectively. Moreover, the immune responses can be potentiated by co-expression of interleukins. Future areas of research include improvement of local immunisation efficiency, analysis of in vivo antigen production, unravelling of the Lactobacillus colonisation mechanisms and construction of biologically contained strains.
Similar articles
- Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system.
Norton PM, Le Page RW, Wells JM. Norton PM, et al. Folia Microbiol (Praha). 1995;40(3):225-30. doi: 10.1007/BF02814197. Folia Microbiol (Praha). 1995. PMID: 8919927 Review. - Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence.
Grangette C, Müller-Alouf H, Geoffroy M, Goudercourt D, Turneer M, Mercenier A. Grangette C, et al. Vaccine. 2002 Sep 10;20(27-28):3304-9. doi: 10.1016/s0264-410x(02)00301-8. Vaccine. 2002. PMID: 12213400 - Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria.
Grangette C, Müller-Alouf H, Hols P, Goudercourt D, Delcour J, Turneer M, Mercenier A. Grangette C, et al. Infect Immun. 2004 May;72(5):2731-7. doi: 10.1128/IAI.72.5.2731-2737.2004. Infect Immun. 2004. PMID: 15102782 Free PMC article. - Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
Szatraj K, Szczepankowska AK, Chmielewska-Jeznach M. Szatraj K, et al. J Appl Microbiol. 2017 Aug;123(2):325-339. doi: 10.1111/jam.13446. Epub 2017 Apr 4. J Appl Microbiol. 2017. PMID: 28295939 Free PMC article. Review. - Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.
Robinson K, Chamberlain LM, Lopez MC, Rush CM, Marcotte H, Le Page RW, Wells JM. Robinson K, et al. Infect Immun. 2004 May;72(5):2753-61. doi: 10.1128/IAI.72.5.2753-2761.2004. Infect Immun. 2004. PMID: 15102785 Free PMC article.
Cited by
- High-level mucosal and systemic immune responses induced by oral administration with Lactobacillus-expressed porcine epidemic diarrhea virus (PEDV) S1 region combined with Lactobacillus-expressed N protein.
Liu DQ, Ge JW, Qiao XY, Jiang YP, Liu SM, Li YJ. Liu DQ, et al. Appl Microbiol Biotechnol. 2012 Mar;93(6):2437-46. doi: 10.1007/s00253-011-3734-0. Epub 2011 Dec 2. Appl Microbiol Biotechnol. 2012. PMID: 22134641 Free PMC article. - Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis.
Lindholm A, Smeds A, Palva A. Lindholm A, et al. Appl Environ Microbiol. 2004 Apr;70(4):2061-71. doi: 10.1128/AEM.70.4.2061-2071.2004. Appl Environ Microbiol. 2004. PMID: 15066797 Free PMC article. - Soluble RANKL expression in Lactococcus lactis and investigation of its potential as an oral vaccine adjuvant.
Kim JI, Park TE, Maharjan S, Li HS, Lee HB, Kim IS, Piao D, Lee JY, Cho CS, Bok JD, Hong ZS, Kang SK, Choi YJ. Kim JI, et al. BMC Immunol. 2015 Nov 25;16:71. doi: 10.1186/s12865-015-0132-x. BMC Immunol. 2015. PMID: 26608025 Free PMC article. - Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P, Jones KF, Geller BL. Mannam P, et al. Infect Immun. 2004 Jun;72(6):3444-50. doi: 10.1128/IAI.72.6.3444-3450.2004. Infect Immun. 2004. PMID: 15155651 Free PMC article. - Recent advances in delivery of veterinary DNA vaccines against avian pathogens.
Jazayeri SD, Poh CL. Jazayeri SD, et al. Vet Res. 2019 Oct 10;50(1):78. doi: 10.1186/s13567-019-0698-z. Vet Res. 2019. PMID: 31601266 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous